X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Orchid Chemicals with Merck Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ORCHID PHARMA LTD vs MERCK LTD - Comparison Results

ORCHID PHARMA LTD    Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

MERCK LTD 
   Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ORCHID PHARMA LTD MERCK LTD ORCHID PHARMA LTD/
MERCK LTD
 
P/E (TTM) x -0.2 52.6 - View Chart
P/BV x 0.2 7.9 2.0% View Chart
Dividend Yield % 0.0 0.4 -  

Financials

 ORCHID PHARMA LTD   MERCK LTD
EQUITY SHARE DATA
    ORCHID PHARMA LTD
Sep-13
MERCK LTD
Dec-16
ORCHID PHARMA LTD/
MERCK LTD
5-Yr Chart
Click to enlarge
High Rs1941,060 18.3%   
Low Rs35623 5.6%   
Sales per share (Unadj.) Rs276.5632.4 43.7%  
Earnings per share (Unadj.) Rs-79.245.7 -173.3%  
Cash flow per share (Unadj.) Rs-43.562.3 -69.7%  
Dividends per share (Unadj.) Rs011.00 0.0%  
Dividend yield (eoy) %01.3 0.0%  
Book value per share (Unadj.) Rs53.9388.8 13.9%  
Shares outstanding (eoy) m70.4516.60 424.4%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x0.41.3 31.1%   
Avg P/E ratio x-1.418.4 -7.9%  
P/CF ratio (eoy) x-2.613.5 -19.5%  
Price / Book Value ratio x2.12.2 98.1%  
Dividend payout %024.1 0.0%   
Avg Mkt Cap Rs m8,06713,969 57.7%   
No. of employees `0002.81.6 176.9%   
Total wages/salary Rs m2,5271,487 170.0%   
Avg. sales/employee Rs Th6,956.16,631.9 104.9%   
Avg. wages/employee Rs Th902.5939.2 96.1%   
Avg. net profit/employee Rs Th-1,993.0479.4 -415.7%   
INCOME DATA
Net Sales Rs m19,47710,498 185.5%  
Other income Rs m407242 168.0%   
Total revenues Rs m19,88410,741 185.1%   
Gross profit Rs m1,1031,135 97.1%  
Depreciation Rs m2,519276 914.4%   
Interest Rs m5,2270-   
Profit before tax Rs m-6,2361,102 -565.8%   
Minority Interest Rs m200-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m5110-   
Tax Rs m-125343 -36.5%   
Profit after tax Rs m-5,580759 -735.3%  
Gross profit margin %5.710.8 52.3%  
Effective tax rate %2.031.1 6.4%   
Net profit margin %-28.77.2 -396.3%  
BALANCE SHEET DATA
Current assets Rs m11,0146,410 171.8%   
Current liabilities Rs m32,0608,828 363.2%   
Net working cap to sales %-108.1-23.0 469.0%  
Current ratio x0.30.7 47.3%  
Inventory Days Days9558 164.5%  
Debtors Days Days3438 87.4%  
Net fixed assets Rs m29,4401,406 2,093.3%   
Share capital Rs m705166 424.4%   
"Free" reserves Rs m2,0436,286 32.5%   
Net worth Rs m3,8006,455 58.9%   
Long term debt Rs m9,0180-   
Total assets Rs m46,5108,828 526.8%  
Interest coverage x-0.2NM-  
Debt to equity ratio x2.40-  
Sales to assets ratio x0.41.2 35.2%   
Return on assets %-0.88.6 -8.8%  
Return on equity %-146.911.8 -1,249.0%  
Return on capital %-3.717.1 -21.9%  
Exports to sales %37.98.3 457.4%   
Imports to sales %22.621.0 107.5%   
Exports (fob) Rs m7,378869 848.6%   
Imports (cif) Rs m4,4062,209 199.4%   
Fx inflow Rs m7,513959 783.6%   
Fx outflow Rs m5,6492,612 216.3%   
Net fx Rs m1,865-1,653 -112.8%   
CASH FLOW
From Operations Rs m1,6821,070 157.1%  
From Investments Rs m-9,860-750 1,315.2%  
From Financial Activity Rs m6,644-150 -4,435.1%  
Net Cashflow Rs m-1,535171 -898.2%  

Share Holding

Indian Promoters % 32.3 0.0 -  
Foreign collaborators % 0.0 51.8 -  
Indian inst/Mut Fund % 4.6 18.2 25.3%  
FIIs % 3.3 1.0 330.0%  
ADR/GDR % 4.6 0.0 -  
Free float % 55.3 29.1 190.0%  
Shareholders   84,811 28,591 296.6%  
Pledged promoter(s) holding % 54.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ORCHID PHARMA LTD With:   DR. REDDYS LAB  STERLING BIOTECH  ASTRAZENECA PHARMA  SUVEN LIFE  IPCA LABS  

Compare ORCHID PHARMA LTD With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Continue Downtrend, BOB-Vijaya-Dena Merger, and Top Stocks in Action Today(Pre-Open)

Share markets in India continued their momentum and ended in red yesterday. Sectoral indices traded in red, with stocks in the realty sector, power sector and PSU sector leading the losses.

Related Views on News

ORCHID PHARMA LTD Announces Quarterly Results (4QFY18); Net Profit Up 50.8% (Quarterly Result Update)

Aug 24, 2018 | Updated on Aug 24, 2018

For the quarter ended March 2018, ORCHID PHARMA LTD has posted a net profit of Rs 924 m (up 50.8% YoY). Sales on the other hand came in at Rs 2 bn (down 24.0% YoY). Read on for a complete analysis of ORCHID PHARMA LTD's quarterly results.

MERCK LTD Announces Quarterly Results (1QFY19); Net Profit Up 63.1% (Quarterly Result Update)

Aug 8, 2018 | Updated on Aug 8, 2018

For the quarter ended June 2018, MERCK LTD has posted a net profit of Rs 328 m (up 63.1% YoY). Sales on the other hand came in at Rs 2 bn (down 17.1% YoY). Read on for a complete analysis of MERCK LTD's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

In a Crisis, if Petrol Prices Hit Rs 100, This Stock Could Be a Good Buy(The 5 Minute Wrapup)

Sep 6, 2018

The rise in the crude oil price is a major reason for the fall in the market. If crude oil prices keep on rising, what will happen to stocks?

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

Hurricanes Threaten Oil Spike, but the Saudis are Selling...(Vivek Kaul's Diary)

Sep 6, 2018

Oil prices are rising and could go even more higher amid rising tensions in Middle East.

Should You Be Worried About the Rising Dollar?(Chart Of The Day)

Sep 7, 2018

While the rupee has deprecated by about 5% annually since 1990 against the dollar, the BSE Sensex has returned 14% annually in the same period.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ORCHID PHARMA LTD SHARE PRICE


Sep 18, 2018 (Close)

TRACK ORCHID PHARMA LTD

  • Track your investment in ORCHID PHARMA LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ORCHID PHARMA LTD

ORCHID PHARMA LTD 8-QTR ANALYSIS

COMPARE ORCHID PHARMA LTD WITH

MARKET STATS